Difference between revisions of "Bavituximab (PGN-401)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "2 PubMed]" to "2/ PubMed]") |
Warner-admin (talk | contribs) |
||
| Line 7: | Line 7: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' PGN-401 |
*'''Brand name:''' Tarvacin | *'''Brand name:''' Tarvacin | ||
Revision as of 00:20, 29 July 2023
Mechanism of action
Binds to phosphatidylserine, provoking an immune response.
Preliminary data
Non-small cell lung cancer
- Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. Epub 2014 Aug 24. link to original article PubMed
Also known as
- Code name: PGN-401
- Brand name: Tarvacin